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Abstract
Background and Aims: ELISA is still used as primary test for diagnosis HBV disease. However, ELISA-positive
patients were marked as HBV inactive after confirmation with PCR and vice versa. Our aim was to assess the
performance of new cut-off value of ALT, HBV DNA load and significance of AST as screening tool for HBeAg (-)
chronic active or inactive patients in Pakistani population.
Materials and methods: In a cross-sectional, cohort study, 567 HBeAg (-) patients followed for one year were
selected. Patients with persistent elevated ALT than normal and HBV DNA ≥ 100,000 copies/mL were taken as
active chronic. Diagnostic values for ALT, AST and HBV DNA load in HBV HBeAg (-) chronic active and inactive
patients compared using receiver operation characteristic (ROC) curves.
Results: Of 567 HBeAg (-) patients, 228 were classified as chronic inactive and 339 as active. HBV infection was
dominant in male. Serum ALT, AST and HBV DNA levels showed significant and high AUROC to differentiate
chronic HBeAg (-) inactive patients from active. AUROC for Serum ALT, AST and HBV DNA were observed 0.997,
0.969 and 1.000, respectively. For revised cut off value for ALT (30 IU/L for male and 19 IU/L for female) and HBV
DNA load ≥100,000 copies/mL, a PPV of 97%, NPV of 94%, a sensitivity of 98%, and a specificity of 92% was
observed to discriminate active carriers from inactive carriers. We also observed 93.5% specificity, 83.1% sensitivity,
82% PPV and 89.5% NPV for AST ≤20 IU/L to differentiate inactive carriers from active ones in our study group.
Conclusions: Revised cut off value of ALT and NIH derived HBV DNA value can better discriminate between
HBeAg (-) chronic active and inactive patients.
Introduction
Almost 170-200 million of the world population is
infected with HBV, leading to world’s most common
cancer “Hepatocellular carcinoma (HCC)”,c a u s i n g
nearly one million deaths per year. Approximately, 20%
of chronic HBV patients have eventually progressed to
liver cirrhosis, and some infections have evolved into
HCC in a substantial number of patients [1,2].
The most common contradiction in diagnosis of HBV
patients is the differentiation of chronic active cases
from the inactive carriers, as they share same serological
profile. Diagnosis of disease outcome in these patients
with PCR and HBV DNA levels assay, and defining the
state of infection with these tools is emerging during
last decade [3-5]. However, in many countries and
regions like United States, Western Europe and other
high or middle income countries, ELISA is still used
and majority of the positive tests are not confirmed by
PCR. It is interesting to note that many HBeAg (-)
patients showed presence of chronic active HBV in
further screening by PCR and vice versa [6]. To differ-
entiate active chronic HBV from inactive carrier state,
an arbitrary serum HBV DNA level of 100000 copies/
mL has been proposed by the United States national
Institute of health (NIH) [7]. During HBV disease pro-
gression, after seroconversion (HBeAg (+) to HBeAg (-),
HBeAg consists of two clinical forms; one known as
chronic inactive with low persistant aminotransferase
levels and HBV DNA levels (≤ 100,000 copies/ml) and
second with no HBeAg, high ALT and HBV DNA levels
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Pakistan, many patients refused to do PCR and liver
biopsy procedure due to poverty and cost of these tests.
Beside these challenges, the growing concern is the early
detection of viral hepatic disease and liver damage. For
this purpose, in routine laboratory tests, elevated alanine
aminotransferase (ALT) levels are used as indicators of
liver cell injury and as non-invasive diagnostic tests [8].
Elevated AST levels are usually predominant in liver cir-
rhosis with increased ALT levels [9,10]. During assess-
ment of liver disease due to hepatitis, serum AST and
ALT levels are most commonly used serum markers to
detect acute and chronic hepatocytes cytotoxicity
[11-13]. Now a days, the main emphasis of workers is
early detection of liver damage due to chronic HBV,
however, there is always questions about the effective-
ness of these test because of their low sensitivity [14,15].
Several studies in Italy, China, Korea and Hong Kong
showed that ALT levels higher than the normal limits
are strongly associated with an increased risk of liver
cirrhosis in HBV infected patients [16-19]. Recent stu-
dies revealed that in patients with HBeAg (-), high ALT
levels greater than 0.5x to the upper limit of normal
(ULN) relate to advance fibrosis and ALT > 30 IU/L
and 19 IU/L in male and female respectively, with base
line HBV DNA levels > 100000 copies/ml; can better
differentiate between active chronic HBV patients from
inactive chronic carriers [11,12,20-22]. While, Degerte-
kin et al. proposed HBV DNA cutoff values of 5000
copies/mL to differentiate between active chronic HBV
patients from inactive chronic carriers [23]. These stu-
dies indicates ALT level as a reliable serum marker lead-
ing to fact that HBV natural history can vary from one
population to another [24]. Therefore, we should deter-
mine more reliable cutoff value for serum ALT and
AST levels to predict active HBV patients according to
our population.
The aim of our study was to assess the relationship
between HBV DNA load, AST and ALT levels in
HBeAg (-) patients, review the performance of serum
ALT and HBV DNA levels as the screening tool for
liver disease and to find whether new cutoff values of
ALT and HBV DNA are able to predict HBV infection
in Pakistani population. The need of PCR and invasive
procedure liver biopsy may be eradicated if the serum
biochemical marker ALT with high positive or negative
predictive values of HBeAg (-) patients can be obtained
and thus minimize the cost of PCR and therapy time.
Material and methods
Patients
Patients of this study were the native Pakistani people
referred to Pathology department, Jinnah Hospital,
Lahore, Pakistan, for biochemical and serological tests.
This retrospective cross-sectional study was carried out
from March 2008 to September 2009 with collaboration
of National Centre of Excellence in Molecular Biology,
University of the Punjab, Lahore, Pakistan. Blood sam-
ples (10 mL) collected from each patient tested for
HBsAg and HBeAg by ELISA. All patients did not have
any history about HBV vaccination or disease infection,
and/or other type of hepatitis. The routine liver function
tests (LFTs) were estimated for each patient in hospital
laboratory. Patients with positive serology and/or posi-
tive test for HBV alone and no evidence of liver failure
were included in this study. Informed consents were
obtained from patients containing their bio data and lab
results. This study was approved by the Institutional
ethics committee.
Laboratory assays
Test for HBsAg and HBeAg were done by using ELISA
kits (Abbot Diagnostics). Serum ALT and AST levels
were measured by using commercially available Hitachi-
7600 series automatic analyzer. The normal limits con-
sidered for ALT was 40 IU/L and for AST 35 IU/L.
Serum HBV DNA was evaluated by using commercially
available polymerase chain reaction assay (Amplicor
HBV Moniter test; Roche Diagnostic System, Inc.,
Branchburg, New Jersey) with lower limit of detection
80 copies/mL and accurate range 500-200,000 copies/
mL according to manufacturer protocol.
Selected patients were HBeAg (-) with base line ALT
determined at first visit. Patients ALT levels were deter-
mined four times every three months. Patients were
divided into two groups as inactive (A) and active (B)
chronic carriers based on HBeAg absence, liver diagno-
sis by ultrsonography, persistent ALT levels and HBV
DNA load. Patients with ≥ 100000 HBV DNA copies/
mL and continual elevated ALT levels were considered
as active chronic carriers.
Statistical analysis
Statistical analysis was performed using the statistical
package for social studies (SPSS) version 16 for win-
dows. Student t-test and chi-square tests were applied
to evaluate differences in proportions. P value <0.05 was
considered significant. Univariate analysis includes the
variables age, HBV DNA levels, ALT and AST. Gender
and PCR results were taken as independent categorical
factors. Spearman correlation was used to assess the
association between two quantitative variables. The diag-
nostic validity of serum ALT, AST and HBV DNA load
and their combination were tested for classification of
HBeAg (-) patients into active and inactive chronic
patients. ROC curves were drawn for predicting values
of ALT, AST and ALT at specific cut off values. Cutoff
values for AST and ALT were 40 and 35 IU/L for each
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2000, 5000, 20,000, 50,000 and 100,000 copies/mL,
respectively. New cut off values with high sensitivity,
specificity, PPV and NPV were also predicted.
Results
Patient’s clinical characteristics
A total of 567 HBeAg (-) patients were selected for this
study. Patient’s data is given in Table 1. The mean age
of the patients was 32.20 ± 11.9. Of 567 patients, 228
were classified into HBeAg (-) chronic inactive, while
remaining 339 were active. The age difference between
both groups was not significant (P =0 . 1 8 1 ) .M a l ew e r e
dominant in both groups. Out of 228 inactive and 339
active patients, 58 and 114 were female respectively (P =
0.038). Among 170 chronic inactive male, 168 have ALT
< 30IU/L; while 51 chronic inactive female out of 58,
have ALT < 19 IU/L. Regarding AST levels, 225 inactive
and 74 active carriers have their AST levels < 35 IU/L.
Baseline ALT and AST values were significantly higher
in HBeAg (-) chronic active patients (P < 0.05).
HBV DNA levels were five times elevated in active
carriers (HBV DNA levels = 4.38 × 10
8 (± 1.04 × 10
9)
copies/mL vs 6.9 × 10
4 (± 4.9 × 10
5) copies/mL). More
than 99% (n = 227) inactive carriers patients have HBV
DNA levels less than 50, 000 copies/mL, and below
undetected limits (< 200 copies/mL) in 21 patients.
Application of revised cutoff values
Receiver operating characteristics (ROC) curves were
drawn for ALT, AST and HBV DNA levels. All of them
showed high area under the curve (AUC) to discrimi-
nate HBeAg (-) active carriers from inactive as men-
tioned in Table 2 (see also Figure 1).
We observed approximately same sensitivity and specifi-
city for the HBV DNA level ≥ 50,000 and NIH described
limits ≥100,000 copies/mL. This value was much better
than HBV DNA value of 2000, 5000 and 20,000 copies/
mL. In general cohort, ALT and AST ≤ 20 IU/L were
observed in 200 and 191 patients, respectively. ALT
≤ 30 IU/L showed high sensitivity (99.1%) and specificity
(97.4%), while normal AST value (≤ 35 IU/L) showed high
sensitivity (98.6%) but low specificity (77.8%) to discrimi-
nate active and inactive chronic HBeAg (-) carriers,
respectively. In combination, ALT and HBV DNA levels; if
ALT value were ≥30 IU/L for male and ≥19 IU/L for
female, and HBV DNA load ≥100,000 copies/mL, a PPV
of 97%, NPV of 94%, a sensitivity of 98%, and a specificity
of 92% was observed to discriminate active carriers from
inactive carriers (Table 3).
A statistical significant correlation was found between
HBV DNA levels and ALT in HBeAg (-) chronic active
patients (r = 0.911, P < 0.05). However, no such associa-
tion was observed in case of ALT in chronic inactive
patients and AST in both groups (Figure 2).
Discussion
In this study, we assess the performance of new cut off
values for serum ALT levels in male and female to pre-
dict active HBV in HBeAg (-) patients. As high ALT
levels are thought to be associated with chronic HBV,
and are commonly used during evaluation of HBV
[10,25-28]. It is interesting to know that HBV evaluation
depend on geographical association of the host and viral
factors. Prati et al. proposed new cutoff value of ALT
≥ 30 IU/L in male and ≥19 IU/L in female [12], while
Assy et al. 2009 reported ALT ≥ 30 IU/L in male and
≥ 19 IU/L in female along with HBV DNA levels
≥ 100000 copies/mL can classify a patient into the active
carrier state [22]. Although, serum AST levels are not
thought to be incredibly useful predictor of HBV dis-
ease, we also evaluate their performance either they are
useful or not for discriminating HBeAg (-) chronic
active from inactive patients.
Previous studies reported raised serum ALT levels
from ULN can predict liver dysfunction with 90% speci-
ficity and 56% sensitivity [29], but according to Kim
et al. prior testing of ELISA along with ALT level can
better predict liver function as compared to only ALT
levels [30]. This is particularly important because with-
out performing PCR and liver biopsy, the decision as to
predict HBeAg (-) chronic inactive is difficult. ROC
curve analysis was performed to find out an accurate
cutoff value for ALT, AST and HBV DNA load to guess
HBeAg (-) inactive chronic patients from active (Table 2
and 3). Serum ALT, AST and HBV DNA levels were
f o u n dt ob eh i g h l ys i g n i f i c a n tw i t hi m m e n s eA U R O C .
Their performance was assessed by using different cut
off values irrespective of patient’s gender. We observed
same results as described by Prati et al. [12] and Assy et
Table 1 Clinical characteristics of HBsAg positive patients
Patients characteristics Inactive carriers n = 228 Active carriers n = 339 P-value
M/F 170/58 225/114 0.038
Age 31.3 ± 12.1 32.75 ± 11.7 0.181
ALT (IU/L) 17.3 ± 4.3 70.3 ± 15.1 0.000
AST (IU/L) 15.9 ± 7.1 48.4 ± 22.6 0.000
HBV DNA (copies/mL) 4.9 × 10
3 6.5 × 10
8 0.000
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copies/mL showed high sensitivity, specificity, PPV and
NPV to differentiate HBeAg (-) inactive chronic patients
from active. In combination (ALT and HBV DNA
levels) we observed higher sensitivity (98%) and NPV
(94%) than previously described [22] (92% and 86%,
respectively) (Table 3).
Although Borg et al. found AST level as an important
predictor during same circumstances [31], and in our
study single AST value (≤ 20 IU/L) also showed high sen-
sitivity and specificity, its prognostic ability was not better
than serum ALT and HBV DNA. Our results are in agree-
ment with Assay et al [22]. that the new baseline value for
ALT levels (30 IU/L for male and 19 IU/L for female)
notably perform well than AST as given in Table 3.
We detect HBV DNA in all patients. By using new cut
off value of ALT, HBV DNA cut off values 50, 000 and
100,000 copies/mL showed same investigative perfor-
mance and were better than 2000, 5000 and 20,000
copies/mL. These results indicate that NIH proposed
HBV DNA levels limits are useful, and our findings are
according to the study by Assy et al. [22] as given in
Table 3. As HBV DNA load and liver damage appears
to be different in HBeAg (+) and negative patients. In
HBeAg (+) patients, no correlation was found between
severity of liver damage and HBV DNA load [32-34]. In
r e c e n ts t u d yb yK i met al. (2011) validate the perfor-
mance of ALT and HBV DNA, and found that these
markers may also used for discriminating patients with
HBeAg (-) active carriers from inactive [35]. In our
study, HBV DNA load was five times higher in chronic
active patients. We also observed a positive significant
correlation between HBV DNA levels and ALT
in chronic active patients (Figure 2) leading to the
conclusion that inflammation increases in patients with
elevated HBV DNA levels as HBeAg has immunomodu-
latory action [36]. Recent studies showed that for
HBeAg (-) patients, low HBV DNA levels are associated
with less liver damage although some studies were
unable to observe such relationship [37,38]. These find-
i n g ss u g g e s tt h a tH B VD N Al o a da n dA L Ta r em o s t
convenient techniques to predict active chronic HBV in
HBeAg (-) patients.
Although, there are some limitations in our study like
absence of liver biopsy data, HBV genotyping and/or a
short period of follow up; yet the population size in this
study is far larger than reported by others. In conclu-
sion, we verified the new cut off value of ALT and
found better results than previously described and also
found AST as good predictor.
Table 2 ROC curve analysis of serum AST, ALT and HBV
DNA levels
Test Result
Variable(s)
Area SE P-
value
95% C I
Lower
Bound
Upper
Bound
AST 0.969 0.006 0.000 0.957 0.982
ALT 0.997 0.002 0.000 0.994 1.001
HBV DNA level 1.000 0.000 0.000 1.000 1.000
Figure 1 ROC curve of serum ALT, AST and HBV DNA levels for
HBeAg (-) patients showed serum ALT, AST and HBV levels
could better predict HBV chronic active carriers at given cutoff
value.
Figure 2 Correlation of ALT and AST with HBV DNA levels in
HBeAg chronic inactive and active patients. A and C: association
between ALT and AST with HBV DNA levels in chronic inactive
carriers; B and D: association between ALT and AST with HBV DNA
levels in chronic active carriers.
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